Key Events This Week
2 Mar: Stock hits 52-week low at Rs.3,848 amid ongoing downtrend
4 Mar: New 52-week low of Rs.3,806.05 recorded
5 Mar: Further decline to 52-week low of Rs.3,804.20
6 Mar: Week closes at Rs.3,785.55, marking continued weakness
2 March: Sanofi India Hits 52-Week Low Amidst Continued Downtrend
Sanofi India Ltd’s stock opened the week on a weak note, closing at Rs.3,861.50 on 2 March 2026, down 2.57% from the previous close. The stock touched a fresh 52-week low of Rs.3,848 during the session, extending a three-day losing streak that saw a cumulative decline of 6.86%. This underperformance was sharper than the Sensex’s 1.41% drop, signalling heightened selling pressure on the stock.
The decline was driven by disappointing quarterly results for the December 2025 quarter, where net profit after tax (PAT) fell 33.4% to Rs.61.70 crore and net sales dropped 13.1% to Rs.419.80 crore. These figures underscored ongoing challenges in revenue growth and profitability, contributing to negative investor sentiment. The stock traded below all key moving averages, reinforcing the bearish technical outlook.
4 March: Further Decline to Rs.3,806.05 Amid Mixed Market Conditions
On 4 March, Sanofi India’s shares continued their downward trajectory, closing at Rs.3,827.00, down 0.89% on the day and marking a new 52-week low of Rs.3,806.05. Despite the broader market’s volatility, with the Sensex falling 1.92%, the stock marginally outperformed its Pharmaceuticals & Biotechnology sector peers by 0.46%.
The sustained decline reflected persistent concerns over the company’s long-term growth, with five-year compound annual growth rates (CAGR) showing net sales contracting at 8.74% annually and operating profit declining by 6.37%. Institutional investors maintained a significant 26.86% stake, indicating some confidence in the company’s fundamentals despite the price weakness.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
5 March: Stock Hits Rs.3,804.20 Despite Broader Market Gains
Sanofi India’s shares declined further on 5 March, closing at Rs.3,810.05, down 0.44% on the day and marking yet another 52-week low at Rs.3,804.20. This marked the fifth consecutive day of losses, with the stock falling 7.85% over this period. The decline contrasted with the broader market’s resilience, as the Sensex rose 1.29% and the NIFTY CPSE index hit a new 52-week high.
The stock’s underperformance relative to the market and sector peers highlighted ongoing investor caution. Despite this, Sanofi India’s valuation metrics remained attractive, with a price-to-book value ratio of 11.3 and a dividend yield exceeding 5%. The company’s strong return on equity (ROE) of 49.40% and zero debt-to-equity ratio underscored its financial strength amid challenging market conditions.
6 March: Week Closes at Rs.3,785.55 on Continued Downtrend
The week ended with Sanofi India’s stock closing at Rs.3,785.55 on 6 March, down 0.64% on the day and marking the lowest close of the week. The stock touched an intraday low of Rs.3,796, its lowest level in the past year. Despite the continued downtrend, the stock marginally outperformed its sector peers by 0.38% on the day.
The Sensex declined 0.98% on the same day, trading below its 50-day moving average, signalling broader market weakness. Sanofi India’s Mojo Score remained subdued at 38.0 with a Sell grade, reflecting cautious market sentiment. The company’s recent quarterly results and negative long-term growth trends continued to weigh on the stock, although its strong balance sheet and attractive dividend yield provided some support.
Holding Sanofi India Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-02 | Rs.3,861.50 | -2.57% | 35,812.02 | -1.41% |
| 2026-03-04 | Rs.3,827.00 | -0.89% | 35,125.64 | -1.92% |
| 2026-03-05 | Rs.3,810.05 | -0.44% | 35,579.03 | +1.29% |
| 2026-03-06 | Rs.3,785.55 | -0.64% | 35,232.05 | -0.98% |
Key Takeaways
Sanofi India Ltd’s stock experienced a sustained downtrend this week, marked by multiple 52-week lows and a total decline of 4.48%. The stock underperformed the Sensex’s 3.00% fall, reflecting company-specific challenges amid broader market volatility.
Financial results for the December 2025 quarter revealed a sharp 33.4% drop in PAT and a 13.1% decline in net sales, reinforcing concerns about the company’s growth trajectory. Long-term negative trends in sales and operating profit further dampened investor sentiment.
Despite the price weakness, Sanofi India maintains a strong balance sheet with zero debt and a high return on equity of 49.40%. Its valuation metrics, including a price-to-book ratio near 11.2 and a dividend yield above 5%, remain attractive relative to peers.
Institutional ownership at 26.86% suggests some confidence in the company’s fundamentals, although the downgrade to a Sell mojo grade and a low mojo score of 38.0 indicate caution from quantitative models.
Technical indicators remain bearish, with the stock trading below all major moving averages. The mixed signals from the broader market, including the Sensex’s position below its 50-day moving average, add to the uncertain near-term outlook.
In summary, Sanofi India Ltd’s week was characterised by persistent selling pressure driven by weak financial performance and negative growth trends, offset partially by strong balance sheet metrics and attractive valuation ratios.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
